News

The Lancet2d
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 ...
cCentre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health ...
C&EN6d
Carbonic Anhydrase Inhibitors: X-ray and Molecular Modeling Study for the Interaction of a Fluorescent Antitumor Sulfonamide with Isozyme II and IX
Contribution from the Istituto di Biostrutture e Bioimmagini-CNR, via Mezzocannone 16, 80134 Naples, Italy, Dipartimento delle Scienze Biologiche-Sezione Biostrutture, University of Naples “Federico ...
lupus.bmj6d
LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients ...
inhibitor, approved in multiple countries for the treatment of adults with plaque psoriasis.¹ ² Deucravacitinib demonstrated efficacy across the primary endpoint and all key secondary endpoints in a ...